Margaret M. Madeleine, MPH, PhD
Professor, Epidemiology
Public Health Sciences Division, Fred Hutch
Dr. Margaret Madeleine’s research focuses on the epidemiology of pathogen-associated malignancies. She’s particularly interested in a pathogen called human papillomavirus, or HPV — the virus that causes genital warts — and how the body’s immune response to it may be associated with cancer development and prognosis. Cancers caused by HPV include those of the cervix, throat, anus, vulva and vagina. By analyzing immune system genes known as human leukocyte antigen, or HLA, genes in women with and without cervical cancer, Dr. Madeleine and colleagues found that certain gene variants may affect women’s cancer risk by tolerating HPV infections. These findings ultimately could aid scientists as they develop vaccines to treat cancer in women already infected with HPV. As a public health researcher, Dr. Madeleine is interested in the role of HPV vaccination in preventing HPV-related cancers and the uptake of HPV vaccination in Washington state. Her current research focuses on improving HPV cancer prevention in three priority areas: prophylactic vaccination, screening, and non-surgical treatment of precancers. She is currently the contact PI for the Colaboracion Evita: Cervical Cancer Prevention Center, an NCI funded U54 grant in the US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network (ULACNet). She is a lead investigator on the Estudio Oportunidad, a cervical cancer screening trial being conducted among 600 WLWH in Santo Domingo, Dominican Republic (NCT05556772). Dr. Madeleine also participates in the NCI’s HIV/Cervical Cancer Prevention ‘CASCADE’ Clinical Trials Network as a co-Investigator.
Other Appointments & Affiliations
Research Professor, Department of Epidemiology, University of Washington School of Public HealthResearch Professor, Department of Epidemiology
University of Washington School of Public Health
Education
PhD, Epidemiology, University of Washington, 1996
MPH, Epidemiology, Yale University, 1991
Current Projects
Estudio Oportunidad, ULACNet-302
Lead Investigator – Dr. Margaret M. Madeleine
This prospective cohort study compares different primary screening and triage approaches to improve the accuracy of detection of cervical precancer among women living with human immunodeficiency virus (WLWH) in the Dominican Republic (NCT05556772). We have enrolled 600 participants and follow them for 2 years.
Protocol Chair – Dr. Margaret M. Madeleine
This trial “Expanded use of Thermal Ablation (EXCEL Cohort) and Prophylactic Use of an Extended Probe (PRO Cohort) for Cervical Cancer Prevention in Women Living with HIV,” is a hybrid type 1 effectiveness-implementation randomized control trial being conducted among 1800 WLWH in four sub-Saharan countries (Kenya, Rwanda, Zimbabwe, and South Africa) to assess the effectiveness of prophylactic treatment with thermal ablation to reduce cervical precancer in a vulnerable population.
Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia (VIVA) Trial
Lead Investigators: Anna Wald, MD and Margaret M. Madeleine, Ph.D.
The VIVA clinical trial will tested whether the Human Papillomavirus (HPV) vaccine can improve the health of people who have been previously diagnosed with pre-cancerous lesions. We enrolled men and women in the Seattle area with a history of pre-cancerous lesions, who were randomly assigned to receive either the Gardasil vaccine or a saline solution (placebo) vaccine. Participants were be asked to come to the clinic for a total of 7 visits over 3 years. All participants will receive a total of 3 injections (Enrollment, Month 2, and Month 6) and will complete questionnaires, and have physical exams, blood draws and biopsies of any pre-cancerous lesions (NCT03051516).